• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ALK2受体激酶与FKBP12.6的结合在结构上与ALK2 - FKBP12复合物保守。

ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex.

作者信息

Williams Eleanor, Riesebos Elise, Kerr Georgina, Bullock Alex N

机构信息

Centre for Medicines Discovery, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.

Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 BT Amsterdam, The Netherlands.

出版信息

Biomedicines. 2021 Jan 29;9(2):129. doi: 10.3390/biomedicines9020129.

DOI:10.3390/biomedicines9020129
PMID:33572801
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7911104/
Abstract

The immunophilin FKBP12 is a known inhibitor of type I BMP and TGF-β receptors that competes for binding with their substrate SMADs. FKBP12 and the close paralog FKBP12.6 additionally assemble with ryanodine receptors to control Ca release. Binding of FKBP12.6 to BMP/TGF-β receptors has yet to be investigated, but appears plausible given its high sequence similarity to FKBP12. Here, we found that FKBP12.6 can assemble with BMP and TGF-β-family type I receptors, but not with type II receptors. Cellular immunoprecipitation confirmed similar binding of FKBP12 and FKBP12.6 to the BMP receptor ALK2 (ACVR1), a known target of mutations in the congenital syndrome fibrodysplasia ossificans progressiva (FOP), as well as the pediatric brain tumor diffuse intrinsic pontine glioma (DIPG). SEC-MALS analyses using purified proteins indicated a direct 1:1 interaction between FKBP12.6 and the receptor's cytoplasmic domains. The 2.17 Å structure of this ALK2-FKBP12.6 complex bound to the inhibitor dorsomorphin showed FKBP12.6 binding to the GS domain of ALK2 in a manner equivalent to the FKBP12 complex, with ALK2 residues Phe198 and Leu199 extending into the FK506-binding pocket of FKBP12.6. These findings suggest a level of redundancy in FKBP-family regulation of BMP and TGF-β signaling.

摘要

亲免蛋白FKBP12是已知的I型骨形态发生蛋白(BMP)和转化生长因子-β(TGF-β)受体抑制剂,它能竞争与其底物SMADs结合。FKBP12和关系密切的旁系同源物FKBP12.6还能与雷诺丁受体组装在一起,以控制钙离子释放。FKBP12.6与BMP/TGF-β受体的结合情况尚未得到研究,但鉴于其与FKBP12的高度序列相似性,这种结合似乎是有可能的。在这里,我们发现FKBP12.6可以与BMP和TGF-β家族的I型受体组装在一起,但不能与II型受体组装。细胞免疫沉淀证实,FKBP12和FKBP12.6与BMP受体ALK2(ACVR1)的结合相似,ALK2是先天性进行性骨化性纤维发育不良(FOP)综合征以及儿童脑肿瘤弥漫性固有桥脑胶质瘤(DIPG)中已知的突变靶点。使用纯化蛋白进行的尺寸排阻色谱-多角度光散射(SEC-MALS)分析表明,FKBP12.6与受体的胞质结构域之间存在直接的1:1相互作用。这种与抑制剂多形蛋白结合的ALK2-FKBP12.6复合物的2.17 Å结构显示,FKBP12.6以与FKBP12复合物等效的方式与ALK2的GS结构域结合,ALK2的苯丙氨酸198和亮氨酸199残基延伸到FKBP12.6的FK506结合口袋中。这些发现表明,FKBP家族对BMP和TGF-β信号的调节存在一定程度的冗余。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/f04a9b8aae09/biomedicines-09-00129-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/6eaa092ccf5c/biomedicines-09-00129-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/a63b27875212/biomedicines-09-00129-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/f8f57654169a/biomedicines-09-00129-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/2f89f63768e6/biomedicines-09-00129-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/f04a9b8aae09/biomedicines-09-00129-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/6eaa092ccf5c/biomedicines-09-00129-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/a63b27875212/biomedicines-09-00129-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/f8f57654169a/biomedicines-09-00129-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/2f89f63768e6/biomedicines-09-00129-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe4/7911104/f04a9b8aae09/biomedicines-09-00129-g005.jpg

相似文献

1
ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex.ALK2受体激酶与FKBP12.6的结合在结构上与ALK2 - FKBP12复合物保守。
Biomedicines. 2021 Jan 29;9(2):129. doi: 10.3390/biomedicines9020129.
2
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.FKBP12 和 II 型 BMP 受体对与遗传疾病相关的 ALK2 激活突变体信号转导的影响。
Bone. 2018 Jun;111:101-108. doi: 10.1016/j.bone.2018.03.015. Epub 2018 Mar 15.
3
FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells.FKBP12 是多发性骨髓瘤细胞中 ALK2 活性的主要调节剂。
Cell Commun Signal. 2023 Jan 30;21(1):25. doi: 10.1186/s12964-022-01033-9.
4
ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.ALK2:进行性骨化性纤维发育不良和弥漫性脑桥内在胶质瘤的治疗靶点。
Chem Pharm Bull (Tokyo). 2020;68(3):194-200. doi: 10.1248/cpb.c19-00882.
5
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.3,5-二芳基-2-氨基吡啶ALK2抑制剂的构效关系揭示了对进行性骨化性纤维发育不良致病突变体的结合亲和力未改变。
J Med Chem. 2014 Oct 9;57(19):7900-15. doi: 10.1021/jm501177w. Epub 2014 Sep 4.
6
ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.ALK2 R206H 突变与进行性骨化性纤维发育不良相关,赋予 BMP Ⅰ型受体组成型活性,并使间充质细胞对 BMP 诱导的成骨细胞分化和骨形成敏感。
J Bone Miner Res. 2010 Jun;25(6):1208-15. doi: 10.1359/jbmr.091110.
7
Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.骨形态发生蛋白受体 ALK2 的结构及其在进行性骨化性纤维发育不良中的意义。
J Biol Chem. 2012 Oct 26;287(44):36990-8. doi: 10.1074/jbc.M112.365932. Epub 2012 Sep 12.
8
Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.深入了解激活素 A 诱导骨形态发生蛋白信号转导的分子机制。
Int J Mol Sci. 2020 Sep 5;21(18):6498. doi: 10.3390/ijms21186498.
9
Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.进行性骨化性纤维发育不良新治疗药物的研发
Curr Mol Med. 2016;16(1):4-11. doi: 10.2174/1566524016666151222142446.
10
Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.ALK2/ACVR1是一种多功能受体,其常见突变在不同的儿童肌肉骨骼和神经罕见病中发挥作用。
Cytokine Growth Factor Rev. 2016 Feb;27:93-104. doi: 10.1016/j.cytogfr.2015.12.007. Epub 2015 Dec 28.

引用本文的文献

1
FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells.FKBP12 是多发性骨髓瘤细胞中 ALK2 活性的主要调节剂。
Cell Commun Signal. 2023 Jan 30;21(1):25. doi: 10.1186/s12964-022-01033-9.
2
Editorial of Special Issue "Fibrodysplasia Ossificans Progressiva: Studies on Disease Mechanism towards Novel Therapeutic Approaches".“进行性骨化性纤维发育不良:针对新型治疗方法的疾病机制研究”特刊社论
Biomedicines. 2022 Jan 10;10(1):140. doi: 10.3390/biomedicines10010140.

本文引用的文献

1
Screening and Production of Recombinant Human Proteins: Protein Production in Insect Cells.重组人蛋白的筛选和生产:昆虫细胞中的蛋白生产。
Methods Mol Biol. 2021;2199:67-94. doi: 10.1007/978-1-0716-0892-0_5.
2
Screening and Production of Recombinant Human Proteins: Protein Production in E. coli.筛选和生产重组人蛋白:大肠杆菌中的蛋白生产。
Methods Mol Biol. 2021;2199:45-66. doi: 10.1007/978-1-0716-0892-0_4.
3
Screening and Production of Recombinant Human Proteins: Ligation-Independent Cloning.重组人蛋白的筛选与生产:连接酶独立克隆。
Methods Mol Biol. 2021;2199:23-43. doi: 10.1007/978-1-0716-0892-0_3.
4
Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.深入了解激活素 A 诱导骨形态发生蛋白信号转导的分子机制。
Int J Mol Sci. 2020 Sep 5;21(18):6498. doi: 10.3390/ijms21186498.
5
FKBP51 and FKBP12.6-Novel and tight interactors of Glomulin.FKBP51 和 FKBP12.6-胶联蛋白的新型紧密相互作用蛋白。
PLoS One. 2019 Sep 6;14(9):e0221926. doi: 10.1371/journal.pone.0221926. eCollection 2019.
6
FKBP Ligands-Where We Are and Where to Go?FKBP配体——我们所处的位置与前进的方向?
Front Pharmacol. 2018 Dec 5;9:1425. doi: 10.3389/fphar.2018.01425. eCollection 2018.
7
Overview of refinement procedures within REFMAC5: utilizing data from different sources.REFMAC5 精修过程概述:利用来自不同来源的数据。
Acta Crystallogr D Struct Biol. 2018 Mar 1;74(Pt 3):215-227. doi: 10.1107/S2059798318000979. Epub 2018 Mar 2.
8
Bone Morphogenetic Protein-Based Therapeutic Approaches.基于骨形态发生蛋白的治疗方法。
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):a022327. doi: 10.1101/cshperspect.a022327.
9
Structural Basis of Intracellular TGF-β Signaling: Receptors and Smads.细胞内转化生长因子-β信号传导的结构基础:受体与Smads蛋白
Cold Spring Harb Perspect Biol. 2016 Nov 1;8(11):a022111. doi: 10.1101/cshperspect.a022111.
10
Lessons from ten years of crystallization experiments at the SGC.十年 SGC 结晶实验的经验教训。
Acta Crystallogr D Struct Biol. 2016 Feb;72(Pt 2):224-35. doi: 10.1107/S2059798315024687. Epub 2016 Jan 22.